https://www.thebionews.net/news/articleView.html?idxno=17367

BeyondDx Signs MOU with China’s IVD Company KHB for Joint Development of Lung Cancer and Depression Diagnostics

2025-08-22 09:23:31

[The Bio News – Reporter Inhyo Kang]

BeyondDx, a developer of multi-omics analysis solutions, announced on August 21 that it has signed a Memorandum of Understanding (MOU) with Shanghai Kehua Bio-Engineering (KHB), a leading Chinese in-vitro diagnostics (IVD) company, to jointly develop and commercialize ForeCheck LC (early detection of lung cancer) and an MDD (Major Depressive Disorder) diagnostic platform for global markets.

Founded in 1981, KHB is recognized as one of China’s foremost IVD enterprises, with a broad product portfolio spanning immunoassays, molecular diagnostics, and clinical chemistry. The company has established a wide-reaching sales and marketing network not only across China but also throughout Asia, Europe, and Latin America. Its state-of-the-art manufacturing facilities and R&D centers are internationally certified, ensuring a reliable supply chain and robust global distribution capabilities.

BeyondDx has been advancing high-precision, blood-based early diagnostic technologies through its proprietary AI and machine learning-powered multi-biomarker analysis platform, iDXGate SN. ForeCheck LC leverages liquid biopsy technology to enable early lung cancer screening, while the MDD diagnostic platform combines blood biomarkers with AI algorithms to improve differential diagnosis accuracy for depression, bipolar disorder, and other mental health conditions.

Through this MOU, the two companies will integrate KHB’s global sales and marketing strengths with BeyondDx’s cutting-edge diagnostic technologies to co-develop next-generation diagnostic solutions with both clinical value and commercial competitiveness. The collaboration aims to accelerate commercialization and expand market presence in China and worldwide.

Kwanghyuk Lee, Vice President of BeyondDx, stated, “Leveraging KHB’s global distribution network and market access, BeyondDx’s AI·ML-powered precision diagnostics will reach patients worldwide faster and more effectively. This partnership represents a strategic opportunity to further strengthen the global competitiveness of both companies.”

(Photo caption: From left – Hyuksin Kang, Vice President of KHB, and Kwanghyuk Lee, Vice President of BeyondDx, commemorate the MOU signing. Source: BeyondDx)